Celularity has been created through the contributions of extensive intellectual property, clinical-stage assets, basic and clinical research, and development expertise including:
Founded on the pioneering work of Robert Hariri, MD, PhD, in human placenta-derived cellular therapeutics and biomaterials, Celularity's ability to procure placental stem cells, engineer potential therapies, and deploy potential treatments, positions it to harness the potential of the human placenta and operate along the entire value chain.
"Celularity was formed as a new biotechnology model designed to apply the necessary expertise to harness our placenta discovery platform across a range of unmet medical needs," said Celularity Founder and Chief Executive Officer, Robert J. Hariri, MD, PhD. "With the support of our investors, we are assembling proven regenerative medicine technology and expertise with the goal of developing transformative therapies for fatal and intractable diseases." Dr. Hariri was previously chairman, chief scientific officer and chief executive officer of Celgene Cellular Therapeutics and founder of Anthrogenesis Corporation, which Celgene acquired in 2002. Dr. Hariri is also the co-founder of Human Longevity, Inc.
The formation of Celularity leverages seminal work in the discovery of novel biologically active cell populations in the human placenta with broad therapeutic potential. Celularity will draw upon these proprietary and scalable discoveries that derive from the post-partum human placenta an ethical and renewable source of usable biomaterials. Celularity's development program is focused on an allogeneic platform, leveraging clinically accessible, immune-tolerant cells and biomaterials from a diverse population of informed-consent donors.
Andrew von Eschenbach, MD, among the founding members of the Celularity Board of Directors and former United States Food and Drug Administration (FDA) Commissioner and Director of the National Cancer Institute said, "The pioneering work of Celularity founder Bob Hariri has unleashed the unique properties of placental derived stem cells which have renewed hope for creating safe and effective therapies for the most challenging degenerative diseases." Dr. von Eschenbach added "Celularity with its focus on accelerating innovation in regenerative medicine can become the leading catalyst for cell therapy to address many of the world's unmet medical needs."
Dr. Henry Ji, President and CEO of Sorrento Therapeutics, said, "We are very excited to participate in the creation of Celularity together with Dr. Hariri and his scientific team as well as global leading biopharmaceutical companies, such as Celgene, Human Longevity Inc., and United Therapeutics. The potential for regenerative therapies in treating a wide array of chronic degenerative conditions is well known. We see important synergies for the oncology field and the potential to enhance our fight against malignant cancers. Celularity's technologies, assets, and resources will help advance selected Sorrento cellular therapy programs and potentially transform autologous cellular therapies into affordable and accessible allogeneic cell therapies."
*Interfyl is a registered trademark of Alliqua BioMedical, Inc.
About Celularity, Inc.Celularity, headquartered in Warren, New Jersey, is a biotechnology company with proprietary, leading-edge technology and Intellectual Property to harness the power of the placenta. Their medicine asset portfolio consists of more than 200 issued or pending patents as well as pre-clinical and clinical assets including CAR constructs for allogeneic CAR-T/NK products, licenses of 100+ immunotherapy assets, and commercial stage biosourcing and functional regeneration businesses. For more information, please visitwww.celularity.com. Follow Celularity on Social Media:@Celularity.
About United TherapeuticsUnited Therapeutics Corporationis a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions.
About Sorrento TherapeuticsSorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for immuno-oncology, inflammation and autoimmune diseases. Sorrento's lead product candidates include immunotherapies focused on the treatment of both solid tumors and hematological malignancies, as well as late stage pain products. For more information, please visithttp://sorrentotherapeutics.com
About Human Longevity, Inc.Human Longevity, Inc. (HLI) is the genomics-based, health intelligence company creating the world's largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize health. In addition to the HLIQ Whole Genome and HLIQ Oncology, HLI's business also includes the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health. For more information, please visithttp://www.humanlongevity.comorhttp://www.healthnucleus.com
Media Contacts:CelularityOlivia GoodmanPhone: 212 715-1597olivia.goodman@finnpartners.com
Sorrento Therapeutics, Inc.Alexis Nahama, DVMPhone: 858 203-4120anahama@sorrentotherapeutics.com
Read this article:
Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform - TASS
- Latest Insights on Stem Cell Assay Market Business Strategies, Acquisitions, Revenue Analysis Share, Forecast to 2028 | by Perkinelmer Inc, Promega... - October 13th, 2022
- S.I. school hosts dance-a-thon to support 9-year-old student with sickle cell disease - SILive.com - October 13th, 2022
- Cord blood bank - Wikipedia - October 4th, 2022
- Cell Reprogramming Market is Expected to Record the Massive Growth, with Prominent Key Players Allele Biotechnology, ALSTEM, Applied Biological... - September 16th, 2022
- Pleco Therapeutics Announces Final Close of its Series A Financing Raising 17.3m to Progress its Novel Plecoid Product in Acute Myeloid Leukaemia to... - September 8th, 2022
- Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates - KULR-TV - August 14th, 2022
- Cell Expansion Market Size, Scope, Growth Opportunities, Trends by Manufacturers And Forecast to 2029 Shanghaiist - Shanghaiist - August 5th, 2022
- 3D Bioprinting for Tissue and Organ Regeneration Market worth $424.3 Million by 2030 - Exclusive Report by InsightAce Analytic - Yahoo Finance - July 27th, 2022
- After conquering sickle cell and multiple sclerosis, it was COVID-19 that claimed her - Lynchburg News and Advance - July 11th, 2022
- Stem Cell Therapy Market to Observe Exponential Growth By 2022 to 2030 | Smith, Nephew (UK), MEDIPOST Co Ltd. (South Korea) - Digital Journal - June 22nd, 2022
- Teclison Announces Publication of Phase 1 Data Demonstrating the Safety and Therapeutic Potential of Tirapazamine Chemoembolization for Patients with... - June 22nd, 2022
- This Key Protein Is Essential for Brain Cell Longevity and Growth - SciTechDaily - June 13th, 2022
- Stem Cell Cartilage Regeneration Market to Witness Massive Growth from 2022 to 2030 | Central members covered as a piece of this study incorporate... - June 13th, 2022
- Stem Cell Therapy Market Size, Scope and Forecast | Osiris Therapeutics Medipost Co. Ltd., Anterogen Co. Ltd., Pharmicell Co. Ltd.,... - June 4th, 2022
- Advanced Therapy Medicinal Products (ATMP) Service Providers Market worth $34.59 Billion by 2030 - Exclusive Report by InsightAce Analytic - Yahoo... - June 4th, 2022
- Gene Therapy Market Size, Scope and Forecast | Novartis AG, Biogen, Gilead Sciences MolMed SpA, Spark Therapeutics Orchard Therapeutics plc., SIBIONO,... - June 4th, 2022
- Cell Isolation/Cell Separation Market Size, Scope and Forecast | Beckman Coulter (Subsidiary of Danaher Corporation), Becton, Dickinson and Company,... - June 4th, 2022
- 8 Players Leading the 3D Printed Meat Revolution - 3DPrint.com - May 2nd, 2022
- Penn researchers discover new cell type in human lung with regenerative properties - EurekAlert - April 6th, 2022
- FDA Grants Fast Track Designation to CYNK-001 for AML Treatment - Targeted Oncology - January 5th, 2022
- Stem Cell Therapy: a Look at Current Research, Regulations ... - December 24th, 2021
- Stem Cells Market to Witness Gigantic Growth by 2026 LSMedia - LSMedia - December 24th, 2021
- Peaceful Protest at Cherry Hill Women's Center Warning Public of Increase in Late Term Abortions In New Jersey. - InsiderNJ - October 16th, 2021
- Time to Go Sushi With Cellular Salmon; When Pet Owners Tire of Their Minions - The SandPaper - August 18th, 2021
- Avalon GloboCare, UPMC Hillman and University of Pittsburgh to develop new cancer immunotherapy - Proactive Investors USA & Canada - August 5th, 2021
- John Theurer Cancer Center Investigators Participated in ZUMA-7 Study Showing Value of CAR T-Cell Therapy as Second-Line Treatment for Relapsed Large... - July 21st, 2021
- ExoFlo From Direct Biologics Fulfills Urgent Medical Need in COVID-19 Treatment - PRNewswire - July 21st, 2021
- GXGX Merger: The SPAC News That Has GXGX Stock Soaring - InvestorPlace - July 21st, 2021
- This Startup is Changing the Way Spinal Cord Injury Is Treated Around the World - Entrepreneur - June 23rd, 2021
- Genmab Announces that Janssen has Received European - GlobeNewswire - June 23rd, 2021
- Gene therapy offers potential cure to children born without an immune system - UCLA Newsroom - May 13th, 2021
- Commencement stories from Rowan paint a picture of opportunities near and far - NJ.com - May 13th, 2021
- Vitalant to Hold Blood Donation Event on December 5 in Freehold - TAPinto.net - December 1st, 2020
- Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn - GlobeNewswire - October 23rd, 2020
- Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma... - October 23rd, 2020
- Novel Strategies for Targeting the Guardian of the Genome Emerge - OncLive - October 23rd, 2020
- CRISPR Market to See Massive Growth by 2026 | GE Healthcare Dharmacon, CRISPR Therapeutics, Thermo Fisher Scientific - Aerospace Journal - October 23rd, 2020
- Smith's 2005 stem cell law to be reauthorized by House - InsiderNJ - October 4th, 2020
- Oakland 24-year-old seeking multiethnic bone marrow donor - The Jewish News of Northern California - September 21st, 2020
- 99-million-year-old fight between hell ant and its prey preserved in amber - BBC Focus Magazine - August 12th, 2020
- Vitalant to Hold Blood Donation Drive on August 11 in Atlantic Highlands - TAPinto.net - August 12th, 2020
- Stem Cells Sales Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News - July 7th, 2020
- Mesenchymal Stem Cells Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News - July 7th, 2020
- Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market 2019 Break Down by Top Companies, Countries, Applications, Challenges,... - June 10th, 2020
- Stem Cells Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 - Cole of Duty - June 10th, 2020
- Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX (daratumumab) for the Treatment of Patients with... - June 10th, 2020
- CO2 Incubators Market is Expected to Witness a Steady Growth by 2025 - Farmers Ledger - June 4th, 2020
- Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma GmbH Enter into Strategic Clinical and Commercial Manufacturing Agreements with... - May 13th, 2020
- Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), for the Treatment... - May 6th, 2020
- CO2 Incubators Market Update: Uncover the Business Strategies of Leaders & Laggards of the Market - 3rd Watch News - March 6th, 2020
- SpaceX set to launch Falcon 9 rocket and Dragon capsule from Cape Canaveral this week - Florida Today - March 4th, 2020
- Are stem cells really the key to making humans live longer? - Wired.co.uk - February 16th, 2020
- Musicians and community coming together in Asbury Park to help Point Pleasant 3-year old - Asbury Park Press - February 12th, 2020
- TV Guy: A return to history with Auschwitz Untold - New Jersey Herald - January 27th, 2020
- Europe's guardian of stem cells and hopes, real and unrealistic - FRANCE 24 - January 20th, 2020
- Horizon Discovery to Provide Access to Novel Base Editing Technology - Yahoo Finance - January 15th, 2020
- John Theurer Cancer Center Announces Appointment of Five New Physicians - Newswise - January 15th, 2020
- Horizon to provide access to novel base editing technology - SelectScience - January 15th, 2020
- Reviewing Phibro Animal Health (NASDAQ:PAHC) & AgeX Therapeutics (NASDAQ:AGE) - Riverton Roll - January 15th, 2020
- Stemming the Tide Confronting Anti-Semitism in the 21st Century - The Times of Israel - January 5th, 2020
- Weekly pick of Neuroscience news from around the world - Brain Tumour Research - November 30th, 2019
- Comparing of Rigel Pharmaceuticals Inc. (RIGL) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - The Broch Herald - November 28th, 2019
- Celgene to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annual Meeting - Business... - November 6th, 2019
- Reviewing Surface Oncology Inc. (SURF)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - FinanceMercury - November 6th, 2019
- Reviewing Magenta Therapeutics Inc. (MGTA)'s and PTC Therapeutics Inc. (NASDAQ:PTCT)'s results - FinanceMercury - November 6th, 2019
- Reviewing Capricor Therapeutics Inc. (CAPR)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - FinanceMercury - November 6th, 2019
- Live Cell Imaging Consumables Market Evolving to a Next-Generation Strategy with New Partnerships, Technologies and Targets by 2023 key players LCC... - November 6th, 2019
- Contrasting of Spero Therapeutics Inc. (SPRO) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - FinanceMercury - November 6th, 2019
- PTC Therapeutics Inc. (PTCT) and Jounce Therapeutics Inc. (NASDAQ:JNCE) Comparing side by side - FinanceMercury - November 6th, 2019
- Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and HOOKIPA Pharma Inc. (NASDAQ:HOOK) - MS Wkly - November 2nd, 2019
- Reviewing Brainstorm Cell Therapeutics Inc. (BCLI)'s and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)'s results - MS Wkly - November 2nd, 2019
- Reviewing ImmunoGen Inc. (IMGN)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - November 2nd, 2019
- On Stage: Allegaeon ready to rock Philly - The Unionville Times - November 2nd, 2019
- Comparison of Merus N.V. (MRUS) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly - October 14th, 2019
- Reviewing Curis Inc. (CRIS)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 14th, 2019
- Comparing of NewLink Genetics Corporation (NLNK) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly - October 14th, 2019
- Reviewing Morphic Holding Inc. (MORF)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 14th, 2019
- Reviewing PTC Therapeutics Inc. (PTCT)'s and Inovio Pharmaceuticals Inc. (NASDAQ:INO)'s results - MS Wkly - October 14th, 2019
- Comparing of Osmotica Pharmaceuticals plc (OSMT) and VistaGen Therapeutics Inc. (NASDAQ:VTGN) - MS Wkly - October 14th, 2019
- PTC Therapeutics Inc. (PTCT) and MacroGenics Inc. (NASDAQ:MGNX) Comparing side by side - MS Wkly - October 14th, 2019